ADHD Drugs Killing Children

by | Jun 18, 2009


A green chalkboard with the message 'I LOVE YOU' written in white chalk.Children taking ADHD stimulant drugs such as Ritalin, Adderall and Concerta are five times more likely to suffer sudden, unexplained death than children who are not taking such drugs according to a new study published in the American Journal of Psychiatry and funded by the FDA and the National Institute of Mental Health. Despite these new findings, however, FDA regulators are urging parents to keep their children on these dangerous drugs.


Ritalin, Adderall and Concerta already carry FDA warnings about risks of heart attack and stroke in children with underlying heart conditions, but this was the first study to investigate whether or not they posed a similar risk to healthy children without those problems.


The study, which compares information about 564 children in the United States who died suddenly and inexplicably between 1985 and 1996.
For every child who died suddenly and inexplicably, the researchers then found another child closely matched in terms of age, sex and other variables who died in a traffic accident.


The researchers found that 10 children in the group that suffered sudden, unexplained death had been taking stimulant drugs, whereas only two children in the group were killed in traffic accidents were taking such medications. That means that the children taking the ADHD drugs were five times more likely to die than those not taking the drugs.


However, FDA officials said that given the seriousness of ADHD and the rarity of sudden death — which strikes fewer than 1 in 10,000 children — the benefits of the drugs outweigh their risks. Agency officials urged parents to discuss concerns with doctors rather than deciding on their own to discontinue a child’s medication. I say its not worth the risk!


According to government researchers, about 2.5 million U.S. children currently take drugs for ADHD. At a rate of 1 in 10,000 children, approximately 250 will die a sudden horrible death from these stimulant drugs. If one of those children happened to be your child, no benefit could outweigh the risk. In the not too distant past, even one death was not acceptable. Why do we now allow the FDA and the Pharmaceutical industry to have such power? Why do we allow them to downplay the statistics to the point that they call 250 deaths a rarity?


There can only be one of two answers – greed or ignorance. Which do you think it is? Sales of these ADHD drugs topped $4.8 billion dollars in the US last year for the most popular brands including Ritalin from Novartis, Adderall from Shire Pharmaceutical and Concerta from Johnson & Johnson, according to the health care analysis firm IMS Health.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

8 + 9 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });